Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 AUG 17 ... million, an 8 percent decrease versus second quarter 2008, with growing sales of AMRIX (cyclobenzaprine hydrochloride extended-release capsules) largely offsetting the continued generic erosion of ACTIQ ...
2009 MAY 18 ... million, a 3 percent decrease versus first quarter 2008, with growing sales of AMRIX(R) (cyclobenzaprine hydrochloride extended-release capsules) largely offsetting the continued generic erosion of the ...
2009 FEB 23 ... generic competition for ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II]. AMRIX(R) (cyclobenzaprine hydrochloride extended-release capsules) sales continued to ramp up with an increase of 28 percent ...
2009 JAN 19 ... based on the Company’s submission of Abbreviated New Drug Application (“ANDA”) for cyclobenzaprine hydrochloride extended release capsules (15 and 30 mg), generic of Amrix(R), to the Food and Drug ...
2008 DEC 8 ... initiated a challenge of the patent listed by Anesta in connection with its Amrix(R) (cyclobenzaprine hydrochloride) extended-release capsules, 15mg and 30mg.
Barr filed its Abbreviated New ...
2008 NOV 3 ... to market and sell a generic version of the 15 mg and 30 mg strengths of AMRIX(R) (Cyclobenzaprine Hydrochloride Extended-Release Capsules). In the Notice Letter, Mylan alleges that the U.S. Patent ...
2008 DEC 8 ... formulations containing the muscle relaxant cyclobenzaprine, including AMRIX(R) (Cyclobenzaprine Hydrochloride Extended-Release Capsules) and expires February 26, 2025.
The lawsuit is ...
2008 JUN 30 ... Patent and Trademark Office has issued a pharmaceutical formulation patent for AMRIX(R) (Cyclobenzaprine Hydrochloride Extended-Release Capsules). U.S. Patent No. 7,387,793 was issued to Eurand Inc., the ...
2007 NOV 26 ... pain franchise sales of $500 - $525 million, which will include sales of AMRIX(TM) (cyclobenzaprine hydrochloride extended-release capsules), oncology franchise sales of $110 - $120 million, and other ...
2008 NOV 10 ... were $117.2 million compared to $121.8 million in the third quarter of 2007. AMRIX(R) (cyclobenzaprine hydrochloride extended- release capsules) sales increased 20 percent over the second quarter 2008. ...
2008 MAY 19 ... of $125.7 million, a decrease of only 4 percent versus 2007, with sales of AMRIX(R) (cyclobenzaprine hydrochloride extended-release capsules) and FENTORA(R) (fentanyl buccal tablet) [C-II] largely ...
2007 SEP 3 ... announced it has signed an agreement to acquire the North American rights to AMRIX(R) (cyclobenzaprine hydrochloride extended-release capsules) from ECR Pharmaceuticals, a privately held company. Two ...
2008 FEB 25 ... of two pivotal randomized, placebo-controlled clinical trials showing that AMRIX(R) (cyclobenzaprine hydrochloride extended-release capsules), a new once-daily extended-release skeletal muscle relaxant, ...
2007 SEP 18 ... announced it has signed an agreement to acquire the North American rights to AMRIX(R) (cyclobenzaprine hydrochloride extended-release capsules) from ECR Pharmaceuticals, a privately held company. Two ...
2008 FEB 25 ... Trial of Patients with Failed Back Surgery Syndrome
206 Efficacy of Cyclobenzaprine Hydrochloride Extended-Release 15 mg and 30 mg Once-Daily for Low Back and Neck Pain Associated with ...
